Dengue Epitope 13
Description
Recombinant Dengue Multiple Epitopes 13 is genetically designed dengue multiple epitopes epi-13 designed especially for lateral flow product, they are selected from dengue genome. The rapid test prepared by this antigen has over 90% sensitivity and specificity over 90% to show quick and strong signal for both dengue IgM and IgG.
Product Specs
Product Science Overview
Dengue virus (DENV) is a mosquito-borne flavivirus responsible for significant morbidity and mortality worldwide. It has four distinct serotypes (DENV1-4), and infection with one serotype provides lifelong immunity to that serotype but not to the others. This can lead to severe dengue upon subsequent infections with different serotypes. Developing effective vaccines against all four serotypes is a major public health priority.
The concept of using multiple epitopes in vaccine design involves combining several short peptides, or epitopes, derived from the virus proteome. These epitopes are selected based on their ability to stimulate the body’s immune response. The goal is to create a vaccine that can induce a broad and robust immune response, targeting multiple aspects of the virus.
The “Dengue Multiple Epitopes 13 Recombinant” refers to a recombinant protein designed to include multiple epitopes from the dengue virus. This approach aims to enhance the immunogenicity and efficacy of the vaccine by presenting multiple targets to the immune system.
-
Design and Development:
- Researchers use bioinformatics tools to identify and select epitopes from different dengue virus proteins that are likely to elicit strong immune responses.
- These selected epitopes are then synthesized and combined into a single recombinant protein.
-
Immunogenicity:
- The recombinant protein is tested for its ability to induce both B cell and T cell responses.
- B cell epitopes are crucial for the production of neutralizing antibodies, while T cell epitopes are important for cellular immunity.
-
Advantages:
- Broad Protection: By including epitopes from all four dengue serotypes, the recombinant protein aims to provide broad protection against dengue.
- Enhanced Immunogenicity: The multiple epitope approach can enhance the overall immunogenicity of the vaccine, making it more effective.
-
Challenges:
- Epitope Selection: Identifying the most effective epitopes that can provide broad and long-lasting protection is a complex task.
- Immune Response: Ensuring that the immune response is balanced and does not lead to adverse effects, such as antibody-dependent enhancement (ADE), is critical.
